Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): A perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 558-561

  Das, Millie ^a   Wakelee, Heather ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; MOTESANIB; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 84873690632     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.10.02     Document Type: Review

References (23)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Sandler A, Gray R, Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
3. Reck M, von Pawel J, Zatlouka P, et al. Phase HI trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
4. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1835-42.
5. Paz-Ares L.G., Biesma B, Heigener D., et al. Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30: 3084-92.
6. de Boer R.H., Arrieta Ó, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067-74.
7. Herbst RS, Sun Y, Eberhardt W.E., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619-26.
8. Scagliotti GV, Krzakowski M, Szczesna A., et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012; 30: 2070-8.
9. Sherman SI, Wirth LJ, Droz J.P., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42.
10. Schlumberger MJ, Elisei R, Bastholt L., et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009; 27: 3794-801.
11. Rosen LS, Kurzrock R, Mulay M., et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 2369-76.
12. Blumenschein GR J.r., Kabbinavar F, Menon H., et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011; 22: 2057-67.
13. Bass MB, Sherman SI, Schlumberger M.J., et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010; 95: 5018-27.
14. Autiero M, Luttun A, Tjwa M., et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-70.
15. Scagliotti GV, Vynnychenko I, Park K., et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paditaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONETI. J Clin Oncol 2012; 30: 2829-36.
16. Dowlati A, Gray R, Sandler A.B., et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14: 1407-12.
17. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009; 15: 3600-9.
18. Nikolinakos PG, Altorki N, Yankelevitz D., et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010; 70: 2171-9.
19. Hanrahan EO, Lin HY, Kim E.S., et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 193-201.
20. Zurita AJ, Jonasch E, Wang X., et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012; 23: 46-52.
21. Lambrechts D, Claes B, Delmar P., et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AVITA and AVOREN randomised trials. Lancet Oncol 2012; 13: 724-33.
22. Zhang W, Dahlberg SE, Yang D, et al. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. J Clin Oncol 2009; 27:15s(abstr 8032).
23. Pan F, Tian J, Zhang X., et al. Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutatioa J Cancer Res Clin Oncol 2011; 137: 1397-408.